Table 1. Demographic, clinical and laboratory data of the studied groups.
| Number = 44 (%) | |
|---|---|
| Age | |
| median(range) | 51 (25–82) |
| Gender | |
| Female | 27 (61.4%) |
| Male | 17 (38.6%) |
|
CRAB criteria
| |
| Hemoglobin (n = 44) | |
| < 10 g/dl | 35 (79.5) |
| ≥ 10 g/dl | 9 (20.5) |
| median(range) | 8.65 (5.3–16) |
| Serum Ca (n = 44) | |
| ≤ 11 mg/dl | 33(75.0) |
| > 11 mg/dl | 11(25.0) |
| median(range) | 9.4 (3.9–14.3) |
| Serum Creatinine (n = 44) | |
| ≤ 2 mg/dl | 27 (61.4) |
| > 2 mg/dl | 17 (38.6) |
| median(range) | 1.2 (0.4–7.8) |
| Osteolytic bony lesions (n = 44) | |
| Negative | 6 (13.6) |
| Positive | 38 (86.3) |
| Other Biochemical laboratory profile | |
| β2 microglobulin | |
| < 3.5 mg/l | 1 (2.3) |
| ≥ 3.5 mg/l | 97.7) |
| Albumin (gm/dl) | |
| median(range) | 3 (2–9) |
| LDH (IU/L) | |
| median(range) | 310 (114–1045) |
| Bone marrow examination | |
| BMA plasma cells (%) | |
| median(range) | 30 (15.0–84.0) |
| BMB CD 138 (%) | |
| median(range) | 80 (20–100) |
| BMB pattern of distribution | |
| Diffuse | 28 (63.6) |
| Interstitial | 16 (36.4 |
| Serum protein electrophoresis and immunofixation | |
| IgA Kappa | 5 (11.4) |
| IgA lambda | 5 (11.4) |
| IgG kappa | 22 (50.0) |
| IgG lambda | 12 (27.3) |
| Free light chain (FLC) | |
| K-FLC | 3 (6.8) |
| L-FLC | 5 (11.4) |
| No FLC | 36 (81.8) |
| Response to treatment (n = 44) | |
| Responders | 16 (36.4) |
| Non-responders | 28 (63.6) |